BioVersys AG (SIX: BIOV), a clinical-stage biopharmaceutical company focused on developing novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria, announced today that its management will present a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference, held September 14-16, 2026 in New York City.
The presentation, scheduled for September 16, 2026, from 12:30 PM to 1:00 PM ET at the Kennedy II room on the 4th floor of the Lotte New York Palace, will be delivered by Hernan Levett, Chief Financial Officer of BioVersys. Additionally, Dr. Marc Gitzinger, Chief Executive Officer, will provide an on-demand presentation starting September 11, 2026 at 7:00 AM ET, with a replay available for 90 days. The webcast can be accessed through the H.C. Wainwright platform or on the BioVersys website in the investor section. Both executives will be available for one-on-one meetings with registered attendees during the conference.
BioVersys is a multi-asset, clinical-stage biopharmaceutical company specializing in the research and development of antibacterial products for serious life-threatening infections caused by MDR bacteria. The company leverages two internal technology platforms, TRIC and Ansamycin Chemistry, to design and develop candidates that overcome resistance mechanisms, block virulence production, and directly affect the pathogenesis of harmful bacteria. This approach aims to identify new treatment options in the antimicrobial and microbiome fields, addressing the high unmet medical need for new therapies against resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders.
The company's most advanced programs include BV100, a Phase 3 candidate for nosocomial infections caused by Acinetobacter baumannii, and alpibectir, a Phase 2 candidate for tuberculosis developed in collaboration with GlaxoSmithKline (GSK) and a consortium from the University of Lille, France. These programs highlight BioVersys's commitment to tackling critical public health threats posed by antimicrobial resistance.
The presentation at the H.C. Wainwright conference provides an opportunity for investors and industry stakeholders to gain insights into BioVersys's pipeline, technology platforms, and strategic direction. With the global rise of antimicrobial resistance, the company's work is of significant importance to public health, potentially offering new treatment options for infections that are increasingly difficult to manage.
BioVersys is headquartered in Basel, Switzerland, a prominent biotechnology hub. For more information about the company and its programs, interested parties can access the investor section of the BioVersys website at www.bioversys.com.
